Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Carisma Therapeutics, Inc. (CARM)
:CARM
RESEARCH TOOLSreports
Holding CARM?
Track your performance easily
CARM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.38 - $2.77
Previous CloseN/A
Volume72.54K
Average Volume (3M)361.40K
Market Cap
$19.06M
Enterprise Value$17.26M
Total Cash (Recent Filing)$25.34M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.60
Next Earnings
Apr 08, 2025EPS Estimate
-0.18Last Dividend Ex-Date
Mar 08, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding41,750,110
10 Day Avg. Volume237,176
30 Day Avg. Volume361,397
Standard Deviation0.30
R-Squared0.08
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.94
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue0.07
Enterprise Value/Gross Profit0.18
Enterprise Value/Ebitda-0.31
Forecast
1Y Price Target
$4.57Price Target Upside893.48% Upside
Rating ConsensusHold
Number of Analyst Covering5
Carisma Therapeutics News
PremiumCompany Announcements
Carisma Therapeutics Appoints Interim VP of Finance
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company expects its current cash runway to last through the third quarter of 2025, providing a degree of financial stability.
Innovative Treatment ApproachThe combination of Carisma's CAR expertise with Moderna's lipid nanoparticle platform to induce CAR expression in vivo editing will allow for an off-the-shelf approach that will reduce costs and substantially expand the access to Carisma's technology.
Partnership ExpansionThe expansion of Carisma's partnership with Moderna to include autoimmune programs in addition to oncology work is viewed as a positive signal.
Bears Say
Analyst DowngradeThe rating for Carisma has been downgraded from Buy to Neutral due to a lack of near-term catalysts and a financing overhang.
Program DiscontinuationCarisma Therapeutics announced the decision to discontinue their lead HER-2 monocyte program CT-0525 due to lack of strong enrollment and evolving clinical landscape.
Workforce ReductionThe company's workforce will be reduced by 34% with associated expenses, indicating a significant reorganization effort.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.43%
Insiders
4.21% Mutual Funds
<0.01% Other Institutional Investors
90.80% Public Companies and Individual Investors
CARM FAQ
What was Carisma Therapeutics, Inc.’s price range in the past 12 months?
Carisma Therapeutics, Inc. lowest stock price was $0.38 and its highest was $2.77 in the past 12 months.
What is Carisma Therapeutics, Inc.’s market cap?
Carisma Therapeutics, Inc.’s market cap is $19.06M.
When is Carisma Therapeutics, Inc.’s upcoming earnings report date?
Carisma Therapeutics, Inc.’s upcoming earnings report date is Apr 08, 2025 which is in 77 days.
How were Carisma Therapeutics, Inc.’s earnings last quarter?
Carisma Therapeutics, Inc. released its earnings results on Nov 07, 2024. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.315 by $0.005.
Is Carisma Therapeutics, Inc. overvalued?
According to Wall Street analysts Carisma Therapeutics, Inc.’s price is currently Undervalued.
Does Carisma Therapeutics, Inc. pay dividends?
Carisma Therapeutics, Inc. pays a Notavailable dividend of $0.361 which represents an annual dividend yield of N/A. See more information on Carisma Therapeutics, Inc. dividends here
What is Carisma Therapeutics, Inc.’s EPS estimate?
Carisma Therapeutics, Inc.’s EPS estimate is -0.18.
How many shares outstanding does Carisma Therapeutics, Inc. have?
Carisma Therapeutics, Inc. has 41,750,110 shares outstanding.
What happened to Carisma Therapeutics, Inc.’s price movement after its last earnings report?
Carisma Therapeutics, Inc. reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.315. Following the earnings report the stock price went down -7.207%.
Which hedge fund is a major shareholder of Carisma Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CARM
---
Company Description
Carisma Therapeutics, Inc.
Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
---
CARM Stock 12 Month Forecast
Average Price Target
$4.57
▲(893.48% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Corvus Pharmaceuticals
―
Fate Therapeutics
―
Kura Oncology
―
Beam Therapeutics
―
Bluebird Bio
―
Best Analysts Covering CARM
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-71.62%
reiterated a buy rating 6 months ago
Copying Naureen Quibria's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -71.62% per trade.
---